title: Evidence for tinnitus-related plasticity in the auditory and limbic system, demonstrated by arg3.1 and c-fos immunocytochemistry.
abstract: Distributions of arg3.1 and c-fos immunoreactive neurons (IRN) in gerbil auditory cortex (AC) and amygdala showed characteristic differences when comparing systemic application of the tinnitus-eliciting drug salicylate with acoustic stimulation or saline injections. In AC, arg3.1 IRN induced by stimulation focused in regions corresponding to the frequency content of the stimulus. Injections of salicylate (350 mg/kg body weight) led to accumulation of arg3.1 IRN in the high frequency domain, while saline injections produced a diffuse distribution. After all treatments, c-fos IRN outnumbered arg3.1 IRN in AC and showed a broad distribution. In subcortical auditory structures arg3.1 IRN were absent in all but one brain. In ventral cochlear nucleus, c-fos IRN were always found after stimulation and often also after saline injections, whereas none were present when injecting salicylate. Similarly, in inferior colliculus, numbers of c-fos IRN were lowest after salicylate injections. In the amygdala, c-fos and arg3.1 IRN were increased substantially after salicylate injections compared to auditory stimulation or saline injections. In particular in its central nucleus, c-fos and arg3.1 IRN were found exclusively after the tinnitus-inducing treatment, suggesting that coactivation of the AC and the amygdala may by an essential feature of tinnitus-related activation.
authors.affiliation: Department of Neuoracoustics, Institute of Zoology, Darmstadt University of Technology, Darmstadt, Germany. mahlke@neuroscience.fu-berlin.de
authors.forename: C
authors.initials: C
authors.lastname: Mahlke
authors.forename: E
authors.initials: E
authors.lastname: Wallhäusser-Franke
mesh_terms: D000161:Acoustic Stimulation; D000679:Amygdala / Q000187:drug effects / Q000503:physiopathology*; D000818:Animals; D001303:Auditory Cortex / Q000187:drug effects / Q000503:physiopathology*; D001306:Auditory Pathways / Q000187:drug effects / Q000378:metabolism; D002452:Cell Count; D017626:Cochlear Nucleus / Q000187:drug effects / Q000378:metabolism; D003598:Cytoskeletal Proteins / Q000378:metabolism*; D005260:Female; D005849:Gerbillinae; D007150:Immunohistochemistry; D007245:Inferior Colliculi / Q000187:drug effects / Q000378:metabolism; D007267:Injections; D008297:Male; D009419:Nerve Tissue Proteins / Q000378:metabolism*; D009473:Neuronal Plasticity; D009474:Neurons / Q000378:metabolism / Q000473:pathology; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism*; D012459:Salicylates / Q000008:administration & dosage / Q000494:pharmacology; D012965:Sodium Chloride / Q000008:administration & dosage / Q000494:pharmacology; D014012:Tinnitus / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*
chemical_list: D003598:Cytoskeletal Proteins; D009419:Nerve Tissue Proteins; D016760:Proto-Oncogene Proteins c-fos; D012459:Salicylates; C092069:activity regulated cytoskeletal-associated protein; D012965:Sodium Chloride